[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chengdu Suncadia Medicine Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":160},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,40,63,86,106,118,139],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100053427","phase-1-phase-i-study-of-hrs-1635-in-b-cell-malignancies-100053427",false,"NCT07583212","Phase I Study of HRS-1635 in B-cell Malignancies","An Open-Label, Multicenter Phase I Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-1635 in Patients With B-Cell Malignancies.","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;\n3. Expected survival time ≥ 12 weeks;\n4. Histologically or cytologically confirmed relapsed\u002Frefractory B-cell malignant tumor;\n5. Females of childbearing potential and male participants whose partners are females of childbearing potential must agree to adopt adequate and effective contraceptive measures during the study period. Female participants must not be breastfeeding;\n6. Participants voluntarily enroll in the study, sign the informed consent form, with good compliance and willingness to cooperate with follow-up procedures.\n\nExclusion Criteria:\n\n1. Tumor infiltration of the central nervous system;\n2. A history of other malignant tumors (excluding the study disease) within 2 years prior to the first administration of the study drug;\n3. A history of allogeneic hematopoietic stem cell transplantation or solid organ transplantation;\n4. Positive for hepatitis B surface antigen (HBsAg) at screening with evidence of viral replication confirmed by HBV-DNA test;\n5. Positive for hepatitis C virus antibody (HCV-Ab) at screening with evidence of viral replication confirmed by HCV-RNA test;\n6. Positive for human immunodeficiency virus (HIV) antigen\u002Fantibody test at screening;\n7. History of major surgery or severe trauma within 28 days prior to the first administration of the study drug;\n8. Presence of severe cardiovascular disease.;\n9. Persistent alcohol or drug abuse;\n10. Inability to take oral medication, or presence of severe gastrointestinal dysfunctional diseases, or history of surgery with severe impact on gastrointestinal function.\n11. Pregnant or lactating females.\n12. Concurrent participation in other interventional clinical trials, or an interval of less than 1 month between the signing date of the informed consent form and the last administration of the study drug in the previous clinical trial;","ALL","18 Years",{"count":19,"type":20},180,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The study is being conducted to evaluate the safety and tolerability of HRS-1635. To observe the Dose-Limiting Toxicity (DLT) , explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of HRS-1635 in participants with B-cell malignancy.",[26],"B-cell Malignancy","RECRUITING","2026-07-09",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":31},"2026-06-30",{"date":35,"type":20},"2029-12",{"name":37,"class":38},"Chengdu Suncadia Medicine Co., Ltd.","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":39},"100053281","phase-1-a-clinical-study-of-hrs-8797-in-healthy-participants-100053281","NCT07698756","A Clinical Study of HRS-8797 in Healthy Participants","A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect Following Single and Multiple Oral Doses of HRS-8797 Tablets in Healthy Subjects","Inclusion Criteria:\n\n1. Healthy men and women aged 18 to 55 years old at informed consent signing\n2. Male body weight ≥50 kg , female ≥45 kg; BMI 18 to 28 kg\u002Fm² at screening and baseline\n3. Have no clinically significant abnormalities at screening and baseline\n4. Fertile females and males with fertile female partners: effective contraception consent, and sustained until 4 weeks after the last dose (abstinence or highly effective contraception); no sperm\u002Fegg donation\n\nExclusion Criteria:\n\n1. A history or current severe diseases of multiple systems, or other diseases interfering with trial results.\n2. Severe infection, trauma, major surgery within 3 months before screening; planned surgery during the trial.\n3. Blood donation\u002Fsevere blood loss (≥400 mL) within 3 months, blood transfusion within 4 weeks before screening; planned blood donation during the trial.\n4. History of drug abuse\u002Fdependence; positive urine drug test at screening. Participation in other clinical trials within 3 months before screening or planned\n5. participation during the trial; within 5 half-lives of a prior drug (whichever is longer).\n6. Smoking history (≥5 cigarettes\u002Fday) within 4 weeks before screening; inability to abstain from tobacco during the trial;\n7. Positive for HBsAg, HIV antibody, Treponema pallidum antibody or HCV antibody at screening.\n8. Special dietary requirements and inability to comply with the unified diet.\n9. Difficulty in swallowing\u002Fvenous blood collection; intolerance to intensive blood sampling.\n10. Other circumstances deemed unsuitable for trial participation by Researcher.",true,"55 Years",{"count":50,"type":20},74,[23],"The purpose of this phase I study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-8797 in healthy participants.",[54],"Atopic Dermatitis","NOT_YET_RECRUITING","2026-07-07",{"date":30,"type":31},{"date":59,"type":20},"2026-07",{"date":61,"type":20},"2027-01",{"name":37,"class":38},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},"100639664","phase-2-a-clinical-trial-of-hrs-3095-in-patients-with-chronic-spontaneous-urticaria-100639664","NCT07613866","A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of HRS-3095 in Patients With Chronic Spontaneous Urticaria","Inclusion Criteria:\n\n1. Participants must be between 18 and 70 years of age, inclusive, at the time of signing the Informed Consent Form (ICF), with no restriction on gender.\n2. Participants must have a history of chronic spontaneous urticaria (CSU) with a disease duration of at least 6 months prior to screening.\n3. Participants must be diagnosed with H1-antihistamine-inadequately-controlled CSU at screening, defined as: having had persistent symptoms of pruritus and wheals for ≥6 weeks prior to screening, despite regular use of second-generation H1-antihistamines during that period.\n4. At randomization, the UAS7 score must be ≥16 (range: 0-42) and the HSS7 score ≥ 8 (range: 0-21).\n5. Participants must have been on a stable dose of the specified second-generation H1-antihistamine for at least 3 days prior to the first UAS score at screening.\n6. Participants must be willing and able to complete logbook entries as required during the study and must have no missing daily UAS scores during the 7 days before randomization.\n7. Participants must voluntarily sign the Informed Consent Form (ICF) before any study-related procedures, be able to communicate effectively with the investigator, and be willing to strictly adhere to the requirements of the study protocol.\n8. Female participants of childbearing potential or male participants with a female partner of childbearing potential must agree to avoid donating sperm or ova and must agree to take highly effective contraceptive measures from the time of signing the ICF until 3 months after the last dose.\n\nExclusion Criteria:\n\n1. Any skin disease that could interfere with study assessment (e.g., chronic inducible urticaria, urticarial vasculitis, atopic dermatitis, psoriasis).\n2. Use of systemic or topical medications with therapeutic or immunomodulatory effects on the study disease during the relevant washout period prior to screening.\n3. Use of investigational drugs or medical devices within 8 weeks or 5 half-lives (if known), whichever is longer, or within 30 days (for small molecules) prior to screening.\n4. Vaccination or exposure to live or attenuated vaccines within 3 months prior to screening or participation in a vaccine-related clinical trial within 3 months prior to randomization.\n5. History or current coagulation-related risk (e.g., bleeding diathesis, coagulopathy, GI bleeding with clinical significance, antiplatelet or anticoagulant use, history of thrombosis or thromboembolic events, or increased risk of thrombosis).\n6. History of liver disease or current treatment for liver disease (e.g., hepatitis, cirrhosis, liver failure).\n7. History of systemic antimicrobial use or presence of superficial skin infection (e.g., impetigo) within 4 weeks prior to screening.\n8. History of malignancy or current malignancy (excluding completely resected and recurrence-free basal cell carcinoma, squamous cell carcinoma, or cervical intraepithelial neoplasia).\n9. Major surgery performed within 3 months prior to randomization or planned during the study.\n10. Serious concomitant disease or any condition judged by the investigator to make the participant unsuitable for study participation.\n11. Abnormal findings in vital signs, physical examination, laboratory tests, ECG, chest X-ray\u002FCT, or abdominal ultrasound during screening that have clinical significance and may affect study validity or participant safety.\n12. Pregnant or breastfeeding women.\n13. Allergy to the study drug or any of its components.\n14. History of alcohol abuse within 6 months prior to screening (e.g., \\> 14 units\u002Fweek) or history of illicit drug abuse within 6 months prior to screening.\n15. Any condition judged by the investigator that may affect the safety or efficacy evaluation of the study drug or participant compliance with the study procedures or diary.","70 Years",{"count":72,"type":20},190,[74],"PHASE2","The study is being conducted to evaluate the efficacy, and safety of HRS-3095 with Chronic Spontaneous in adults, and to explore the reasonable dosage of HRS-3095 for Chronic Spontaneous Urticaria.",[77],"Chronic Spontaneous Urticaria","2026-05-22",{"date":80,"type":31},"2026-05-29",{"date":59,"type":20},{"date":83,"type":20},"2027-03",{"name":37,"class":38},2,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":21,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":105,"locationsCount":39},"100635321","phase-1-a-clinical-study-of-hrs-5765-in-healthy-participants-100635321","NCT07551167","A Clinical Study of HRS-5765 in Healthy Participants","A Randomized, Double-Blind, Dose-Escalation, Placebo-Parallel Controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of HRS-5765 in Healthy Subjects, as Well as the Effect of Food on the Pharmacokinetics of HRS-5765 and the Effect of HRS-5765 on CYP3A4 Metabolic Enzymes","Inclusion Criteria:\n\n1. Healthy men and women aged 18 to 65 years old at informed consent signing.\n2. Male body weight ≥ 50 kg and \\\u003C 90.0 kg, female ≥ 45 kg and \\\u003C 90.0 kg; BMI 19 to 26 kg\u002Fm² at screening and baseline.\n3. Have no clinically significant abnormalities at screening and baseline.\n4. Fertile females and males with fertile female partners: effective contraception consent, and sustained until 1 week after the last dose (abstinence or highly effective contraception); no sperm\u002Fegg donation.\n\nExclusion Criteria:\n\n1. A history or current severe diseases of multiple systems, or other diseases interfering with trial results.\n2. Severe infection, trauma, major surgery within 3 months before screening; Planned surgery during the trial.\n3. Blood donation\u002Fsevere blood loss (≥ 400 mL) within 3 months, blood transfusion within 4 weeks before screening; Planned blood donation during the trial.\n4. History of drug abuse\u002Fdependence; positive urine drug test at screening. Participation in other clinical trials within 3 months before screening or planned.\n5. Participation during the trial; Within 5 half-lives of a prior drug (whichever is longer).\n6. Smoking history (≥ 5 cigarettes\u002Fday) within 4 weeks before screening; Inability to abstain from tobacco during the trial.\n7. Positive for HBsAg, HIV antibody, Treponema pallidum antibody or HCV antibody at screening.\n8. Special dietary requirements and inability to comply with the unified diet.\n9. Difficulty in swallowing\u002Fvenous blood collection; Intolerance to intensive blood sampling.\n10. Other circumstances deemed unsuitable for trial participation by researcher.","65 Years",{"count":50,"type":20},[23],"The purpose of this phase I study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of HRS-5765 in healthy participants.",[98],"Heart Failure","2026-05-21",{"date":101,"type":31},"2026-05-26",{"date":103,"type":31},"2026-05-20",{"date":61,"type":20},{"name":37,"class":38},{"id":107,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":24,"conditions":110,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":117,"locationsCount":39},"100637547",{"count":19,"type":20},[23],[26],"2026-05-07",{"date":113,"type":31},"2026-05-13",{"date":115,"type":20},"2026-06",{"date":35,"type":20},{"name":37,"class":38},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":39},"100638372","phase-2-a-trial-to-evaluate-the-long-term-safety-and-tolerability-of-hrs-5965-in-patients-with-primary-iga-nephropathy-100638372","NCT07582133","A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy","A Multicenter, Open-label Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 Capsules in Patients With Primary IgA Nephropathy","Inclusion Criteria:\n\n1. Patients with primary IgA nephropathy who completed treatment in Study HRS-5965-305, or who prematurely discontinued study drug during the maintenance phase following initiation of rescue therapy;\n2. Understand the research procedures and methods, voluntarily participate in this trial and sign the informed consent form in person.\n\nExclusion Criteria:\n\n1. Hypersensitivity to the study drug or its components；\n2. History of immunodeficiency disorders；\n3. History of invasive encapsulated bacterial infection；\n4. History of malignant neoplasm；\n5. The estimated glomerular filtration rate (eGFR) is less than 20 mL\u002Fmin\u002F1.73m2；",{"count":126,"type":20},380,[74],"This study aims to evaluate the long-term safety of HRS-5965 capsules in patients with primary IgA nephropathy, and also to assess its efficacy in reducing 24-hour urinary protein and delaying the decline in eGFR in these patients.",[130],"Primary IgA Nephropathy","2026-05-06",{"date":133,"type":31},"2026-05-12",{"date":135,"type":20},"2026-05",{"date":137,"type":20},"2029-11",{"name":37,"class":38},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":21,"phases":148,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":39},"100594083","phase-3-a-trial-of-hrs-5965-capsule-in-primary-iga-nephropathy-100594083","NCT07014826","A Trial of HRS-5965 Capsule in Primary IgA Nephropathy","Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial, to Evaluate the Efficacy and Safety of HRS-5965 Capsule in Primary IgA Nephropathy","Inclusion Criteria:\n\n1. Able and willing to provide a written informed consent；\n2. Weight ≥35 kg, Body mass index (BMI) \\\u003C 37.5kg \u002Fm2;\n3. Primary IgA nephropathy was confirmed by renal biopsy within 8 years;\n4. 24-UPE≥ 1.0g \u002F24h, or 24-UPCR≥ 0.8g\u002Fg at screen, and 24-UPCR≥ 0.8g\u002Fg prior to randomization;\n5. eGFR≥30 ml\u002Fmin\u002F1.73m2 at screening and prior to randomization; (CKD-EPI formula)\n6. A fertile female subject or a male subject whose partner is a fertile female, who has not had a fertility, sperm\u002Fegg donation plan from the signing of the informed consent to 1 month after the last dose, and voluntarily takes effective contraceptive measures (including the partner);\n7. Understand the research procedures and methods, voluntarily participate in this trial, and sign the informed consent form in person.\n8. Receiving optimal supportive therapy including RAS blockers and stabilizing the dose for at least 12 weeks after reaching the maximum recommended dose or the maximum tolerated dose prior to randomization;\n\nExclusion Criteria:\n\n1. Allergic to any RAS blockers, investigational products, or components as evaluated by the investigator;\n2. Patients with secondary IgA nephropathy as determined by the investigator;\n3. IgA nephropathy with rapid decline of renal function; Kidney pathology indicated that more than 50% of the glomerulus had large crescent body formation, which may affect the study results; Tubule atrophy - interstitial fibrosis of more than 50%;\n4. Patients with a history of immunodeficiency disease; Or in combination with other systemic diseases likely to cause proteinuria; Or with Nephrotic Syndrome;\n5. Have any organ transplant;\n6. Patients with active infection of tuberculosis within 1 year prior to screening, such as liver abscess and pyelonephritis; Or subjects with active infection who requiring intravenous antibiotic therapy within 2 weeks prior to randomization;\n7. Patients with a history of malignant neoplasms;\n8. Patients with a history of severe trauma or major surgery within 12 weeks prior to screening, or who plan to undergo surgery during the study period;\n9. Patients with a history of blood donation or a history of severe blood loss (≥400 mL blood loss) within 12 weeks prior to screening, or who have received blood transfusions within 12 weeks prior to screening;\n10. The presence of a disease or medical condition determined by the investigator might affect drug absorption, distribution, metabolism, and excretion;\n11. As determined by the investigator, the subject has any of the following: progression or recovery of a disease;\n12. Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), or total bilirubin exceeding 3 times the upper limit of normal (ULN) at screening;\n13. Participants who have participated in a clinical trial of any drug or medical device within 12 weeks prior to randomization and are expected to have residual effects of the investigational treatment (as determined by the investigator), or who were within the follow-up period of a clinical study, or within 5 half-lives of the investigational drug, or within 30 days (whichever is older) before screening;\n14. Women who are pregnant or breastfeeding;\n15. A history of drug abuse;\n16. Participants who received systemic glucocorticoid or immune suppressants within 12 weeks prior to randomization and are expected to have during research；\n17. Participants who received biologics or cytokine inhibitor within 6 months prior to randomization and are expected to have during research；\n18. Any physical or mental illness or condition that, as determined by the investigator, is likely to increase the risk of the study, affect the subject's adherence to the protocol, or prevent the subject from completing the study.",{"count":147,"type":20},378,[149],"PHASE3","This multicenter, randomized, double-blind, parallel, placebo-controlled study is being conducted to evaluate the efficacy, and safety of HRS-5965 capsule for primary IgA nephropathy.",[130],"2025-07-31",{"date":154,"type":31},"2025-08-05",{"date":156,"type":31},"2025-06-04",{"date":158,"type":20},"2028-12",{"name":37,"class":38},""]